Pelthos Therapeutics to Merge With Castle Creek Biosciences
Pelthos signed a definitive merger deal. Castle Creek holders will receive 5.2 million PTHS shares, about 32.5%, at closing, plus up to 5.8 million shares upon FDA approval of D—Fi and up to $300 million in milestones. Closing is expected by the end of Q1 2027, subject to conditions.